Lipanthyl (Fenofibrate)

Lipanthyl (fenofibrate) is used to manage disorders of lipid metabolism.

• Hypertriglyceridaemia: reduces very‑low‑density lipoprotein triglycerides and lowers plasma triglyceride concentrations.
• Mixed dyslipidaemia: improves the overall lipid profile by decreasing triglycerides and modestly raising HDL‑cholesterol.
• Primary hypercholesterolaemia (adjunct): used alongside statins to further lower LDL‑cholesterol when diet alone is inadequate.

• Fenofibrate activates peroxisome proliferator‑activated receptor‑α (PPARα) in liver and peripheral tissues. Activation of PPARα up‑regulates genes involved in fatty‑acid β‑oxidation, reduces hepatic triglyceride synthesis, and increases clearance of triglyceride‑rich lipoproteins. The combined effect lowers plasma triglyceride levels, modestly raises high‑density lipoprotein cholesterol, and can modestly reduce low‑density lipoprotein cholesterol.

Fenofibrate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Abdominal discomfort or pain
• Nausea or vomiting
• Headache
• Elevated liver enzymes

Serious or Rare Side Effects

• Rhabdomyolysis with muscle pain and weakness
• Severe hepatic injury or hepatitis
• Acute pancreatitis
• Life‑threatening allergic reactions such as Stevens‑Johnson syndrome

When prescribing Lipanthyl, clinicians should consider several precautionary measures to ensure patient safety.

• Liver function monitoring: assess baseline hepatic enzymes and repeat periodically.
• Renal function assessment: adjust use in patients with impaired kidney function.
• Muscle disorder vigilance: discontinue if unexplained muscle pain, tenderness or weakness occurs.
• Concomitant alcohol use: advise limiting alcohol to reduce risk of liver toxicity.
• Drug interaction caution: avoid use with strong CYP3A4 inhibitors without supervision.
• Store at room temperature: keep in original container, protect from moisture and heat.

Fenofibrate can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Gemfibrozil: markedly increases risk of myopathy and rhabdomyolysis.
• Cyclosporine: raises fenofibrate plasma concentrations, enhancing toxicity.
• High‑dose statins (e.g., simvastatin >20 mg): combined use raises risk of severe muscle injury.
• Warfarin: may potentiate anticoagulant effect, requiring INR monitoring.
• Cholesterol‑binding resins (e.g., cholestyramine): reduce fenofibrate absorption.

Moderate Interactions (Monitor Closely)

• Other fibrates: additive risk of muscle toxicity.
• Niacin: may increase hepatotoxic potential.
• Oral contraceptives: possible increase in liver enzyme elevations.
• Digoxin: fenofibrate may raise digoxin levels.
• Antidiabetic agents (e.g., insulin, sulfonylureas): monitor blood glucose as fenofibrate can affect glycemic control.